Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEIZE-TBI: Levetiracetam vs Lacosamide for Seizure Prevention in TBI
NCT06866691Phase 4Recruiting
- Sponsor
- Wake Forest University Health Sciences
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of lacosamide in post-traumatic seizure (PTS) (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoint: Incidence of Early Post-traumatic Seizure at 7 days. Started Apr 2025; status: recruiting.
02
Drugs
lacosamide
03
Conditions
post-traumatic seizure (PTS)
Beyond the preview
Go deeper on NCT06866691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06866691.